Clinical Trial: Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07376499) titled 'Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction' on Jan. 22.

Brief Summary: To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction

Study Start Date: Jan. 25

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer

Intervention: DRUG: Liposome Irinotecan

Liposome irinotecan(50mg/m^2) wi...